Abstract | PURPOSE: SUBJECTS AND METHODS: This was a single-insititution, open-label, single-group study of symptomatic patients > or = 12 years of age with allergic conjunctivitis. RESULTS: A total of 110 Japanese patients were enrolled. From baseline to week 10, the mean (95% confidence interval) absolute changes were -2.4 (-2.7, -2.2) in ocular itching and the total hyperemia scores were -3.2 (-3.4, -2.9). Mean scores for all other efficacy variables were low at baseline (< or = 2.4) and decreased to < or = 0.6 by week 10. There were no serious adverse events. Mild eye irritation (1 patient) was the only treatment-related event. No safety concerns were identified in a review of the safety results. CONCLUSIONS: Based on this study, olopatadine 0.2% is generally safe, well tolerated and effective when instilled as 2 drops in both eyes twice-daily in Japanese patients with allergic conjunctivitis and is a useful new option for ocular allergy management.
|
Authors | Shigeaki Ohno, Makoto Ando |
Journal | Nippon Ganka Gakkai zasshi
(Nippon Ganka Gakkai Zasshi)
Vol. 116
Issue 9
Pg. 869-79
(Sep 2012)
ISSN: 0029-0203 [Print] Japan |
PMID | 23092094
(Publication Type: English Abstract, Journal Article)
|
Chemical References |
- Anti-Allergic Agents
- Dibenzoxepins
- Olopatadine Hydrochloride
|
Topics |
- Adolescent
- Adult
- Anti-Allergic Agents
(administration & dosage, adverse effects)
- Child
- Conjunctivitis, Allergic
(drug therapy)
- Dibenzoxepins
(administration & dosage, adverse effects)
- Drug Administration Schedule
- Female
- Humans
- Instillation, Drug
- Japan
- Male
- Middle Aged
- Olopatadine Hydrochloride
|